Search by Algolia
Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
QT IMAGING HOLDINGS, INC.QT Imaging Reports 105% Revenue Growth to $2.8 Million, Net Loss Increases to $11.1 Million
INTELLIGENT BIO SOLUTIONS INC.Intelligent Bio Solutions Reports Revenue Decline and Increased Net Loss for Q1 2025
TaoWeave, Inc.Oblong, Inc. Reports Slight Revenue Decline but Improved Net Loss in Q1 2025
CG Oncology, Inc.CG Oncology Reports 90% Revenue Decline and 84% Increase in Operating Expenses for Q1 2025
Candel Therapeutics, Inc.Candel Therapeutics Reports $7.4 Million Net Income in Q1 2025, Significant Turnaround from Prior Year
HYDROFARM HOLDINGS GROUP, INC.Hydrofarm Reports $14.4 Million Net Loss and 25.2% Revenue Decline in Q1 2025
Lionheart HoldingsLionheart Holdings Reports $2.2 Million Net Income for Quarter Ending March 31, 2025
TON Strategy CoVerb Technology Reports 18,543% Revenue Growth to $1.3 Million in Latest Quarter
ARTELO BIOSCIENCES, INC.Artelo Biosciences Reports $2.4 Million Net Loss in Q1 2025, Seeks Additional Funding
ATOSSA THERAPEUTICS, INC.Atossa Therapeutics Reports $6.7 Million Net Loss in Q1 2025, Focuses on Breast Cancer Treatment
BIOFORCE NANOSCIENCES HOLDINGS, INC.BioForce Nanosciences Reports Q1 2025 Financial Results with Increased Net Loss
Ovid Therapeutics Inc.Ovid Therapeutics Reports Q1 2025 Financial Results with Revenue Decline and Reduced Losses
NEUROONE MEDICAL TECHNOLOGIES CorpNeuroOne Reports Q2 2025 Financial Results with Increased Revenue and Reduced Net Loss
Monopar TherapeuticsMonopar Therapeutics Reports $2.6 Million Net Loss in Q1 2025, Increases R&D and G&A Expenses
NetBrands Corp.NetBrands Corp. Reports Improved Q1 2025 Financial Results with Reduced Net Loss
Mereo BioPharma Group plcMereo BioPharma Reports $12.9 Million Net Loss in Q1 2025
ACHIEVE LIFE SCIENCES, INC.Achieve Life Sciences Reports $12.8 Million Net Loss in Q1 2025, Faces Financial Challenges
Y-mAbs Therapeutics, Inc.Y-mAbs Therapeutics Reports 8% Revenue Growth in Q1 2025, Net Loss Improves
Iterum Therapeutics plcIterum Therapeutics Reports Q1 2025 Financial Results, Net Loss Decreases to $4.9 Million
BK Technologies CorpBK Technologies Reports $2.1 Million Net Income and 4.5% Revenue Growth in Q1 2025
Landsea Homes CorpLandsea Homes Reports $310.8 Million Revenue with Net Loss of $7.3 Million in Q1 2025
Passage BIO, Inc.Passage Bio Reports $15.4 Million Net Loss in Q1 2025, Focuses on Gene Therapy Development
Instil Bio, Inc.Instil Bio Reports $28.2 Million Net Loss in Q1 2025, Driven by Increased Restructuring Charges
Cellectar Biosciences, Inc.Cellectar Biosciences Reports 75% Reduction in Financial Losses for Q1 2025
Minerva Neurosciences, Inc.Minerva Neurosciences Reports $3.8 Million Net Loss in Q1 2025, Focuses on Roluperidone Development